博济医药(300404) - 2017 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥34,493,304.69, representing a significant increase of 103.09% year-on-year[7]. - Net profit attributable to shareholders was -¥2,930,400.84, a decline of 163.82% compared to the same period last year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥3,621,518.15, a decrease of 3,514.33% year-on-year[7]. - Basic earnings per share for the reporting period was -¥0.0218, down 163.37% from the previous year[7]. - The weighted average return on net assets was -0.64%, a decrease of 160.26% compared to the same period last year[7]. - Total revenue increased by 121.41% to ¥89,027,964.29 compared to ¥40,209,374.41 in the same period last year, primarily due to growth in clinical research service revenue[17]. - Net profit decreased by 205.12% to -¥3,062,499.40, attributed to increased R&D investment and a decline in gross margin[18]. - The total profit for the year-to-date period was a loss of CNY -3,223,548.10, compared to a profit of CNY 2,628,981.97 in the previous year[46]. - The total comprehensive income for the current period was CNY -3,062,499.40, compared to CNY 2,913,305.61 in the previous period, reflecting a significant downturn[47]. Cash Flow - The company reported a net cash flow from operating activities of ¥2,860,730.01 for the year-to-date period[7]. - Cash flow from operating activities improved significantly to ¥2,860,730.01 from -¥28,200,691.93 in the previous year, indicating better cash collection[19]. - Cash flow from operating activities generated a net amount of ¥7,961,500.44, recovering from a negative cash flow of ¥-23,722,827.02 in the previous period[55]. - The net cash flow from financing activities was 22,663,238.97 CNY, compared to a negative cash flow of 6,667,000.00 CNY in the previous period[56]. - The net increase in cash and cash equivalents for the period was 26,263,720.83 CNY, compared to an increase of 6,488,429.49 CNY in the previous period[56]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥574,006,369.61, an increase of 10.63% compared to the previous year[7]. - The total liabilities increased to CNY 94,761,249.67 from CNY 78,515,132.47, reflecting a rise of about 20.6%[35]. - Fixed assets rose by 66.12% to ¥118,598,845.99, mainly due to the completion of the Guangzhou headquarters office building[17]. - Other current assets decreased by 82.70% to ¥10,923,922.49, mainly due to the maturity and recovery of principal from bank wealth management products[17]. - The company's total cash and cash equivalents at the end of the period stood at ¥153,018,231.21, up from ¥128,911,093.05 at the end of the previous period[54]. Shareholder Information - The total number of shareholders at the end of the reporting period was 13,804[11]. - The largest shareholder, Wang Tingchun, holds 38.51% of the shares, totaling 51,710,000 shares[11]. Expenses - The company reported a significant increase in sales expenses, which rose to CNY 1,751,172.08 from CNY 1,391,056.34, reflecting an increase of approximately 26%[38]. - The company experienced a significant increase in sales expenses, which rose to CNY 4,334,963.54 from CNY 3,550,084.56, reflecting an increase of about 22.1%[44]. - The company reported an increase in management expenses to CNY 27,669,858.46 from CNY 21,591,360.95, which is an increase of about 28.2%[44]. Investment Activities - The company plans to invest in a target company through cash, following the termination of a major asset restructuring due to unfavorable conditions[20]. - Investment income dropped by 97.45% to ¥70,662.28, primarily due to reduced returns from wealth management products[17]. - Cash inflow from investment activities totaled ¥37,000,000.00, down from ¥103,952,764.79 in the previous period[55]. - The company reported cash outflow from investment activities of ¥41,361,018.58, compared to ¥67,074,508.28 in the previous period[55].